Home > Quotes > CNK > Guru Analysis > Kenneth Fisher

Kenneth Fisher Guru Analysis for Cinemark Holdings Inc

Get CNK Alerts
*Delayed - data as of May 24, 2016 15:16 ET  -  Find a broker to begin trading CNK now
Exchange: NYSE
Industry: Consumer Services
Community Rating:
View:    CNK Real Time
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Assessments & Analysis Based on May 23, 2016 close price: $35.82

  for the Price/Sales Investor based on the criteria of Kenneth Fisher. Return to CNK Guru Analysis

All Star Guru Scorecard

Source Go Chart %
Peter Lynch 0%
Benjamin Graham 29%
Validea 43%
Motley Fool 32%
David Dreman 57%
Martin Zweig 62%
Kenneth Fisher 50%
James P. O'Shaughnessy 50%

Detailed Analysis

Guru Score: 50%


The prospective company should have a low Price/Sales ratio. Non-cyclical (non-Smokestack) companies with Price/Sales ratio between .75 and 1.5 are good values. CNK's P/S ratio of 1.43 Based on trailing 12 month sales, falls within the "good values" range for non-cyclical companies and is considered attractive.


Less debt equals less risk according to this methodology. CNK's Debt/Equity of 177.92% is unacceptable, thus failing the test.


This methodology considers companies in the Technology and Medical sectors to be attractive if they have low Price/Research ratios. CNK is neither a Technology nor Medical company. Therefore the Price/Research ratio is not available and, hence, not much emphasis should be placed on this particular variable.

PRELIMINARY GRADE: No Interest in CNK At this Point

Is CNK a "Super Stock"? NO

Price/Sales Ratio: [FAIL]

The Price/Sales ratio is the most important variable according to this methodology. The prospective company should have a low Price/Sales ratio. CNK's Price/Sales ratio of 1.43 does not pass this criterion.


This methodology looks for companies that have an inflation adjusted EPS growth rate greater than 15%. CNK's inflation adjusted EPS growth rate of 7.40% does not pass this test.


This methodology looks for companies that have a positive free cash per share. Companies should have enough free cash available to sustain three years of losses. This is based on the premise that companies without cash will soon be out of business. CNK's free cash per share of 0.07 passes this criterion.


This methodology looks for companies that have an average net profit margin of 5% or greater over a three year period. CNK's three year net profit margin, which averages 6.82%, passes this criterion.

The names of individual investment advisors (i.e., the 'gurus') appearing ON THIS WEBSITE are for identification purposes ONLY. The names are used to identify the methodology as derived from the guru's published sources. The names of the individual gurus are not intended to suggest or imply any affiliation with or endorsement of, or even any agreement with the information displayed on this website personally by such gurus, or any knowledge or approval by such persons of the content on this website. All trademarks, service marks and trade names appearing on this website are the property of their respective owners, and are likewise used for identification purposes only.

The NASDAQ Stock Market, Inc. ("NASDAQ"), its affiliates, third party information providers, or any of these entities' officers, employees, directors, or agents have not: (1) passed on the merit of the information provided on this website or on any of these securities; or (2) endorsed or sponsored any of these securities. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. The information contained on this website is provided for informational purposes only. See Full Disclaimer Below
See Full Disclaimer
The Validea Market Legends ETF (VALX)